Invaluable Guidance: FDA’s Dean of Drug Reviews on “Enrichment Strategies”
This article was originally published in RPM Report
Executive Summary
FDA’s draft guidance on “Enrichment Strategies for Clinical Trials” fulfills an overdue goal from PDUFA IV. It also captures decades of wisdom from the agency’s senior drug review manager.
You may also be interested in...
US FDA “Enriches” Trial Guidance With Recent Examples
Illustrating that principles articulated in 2012 draft are being broadly accepted at FDA, final guidance on enrichment strategies for clinical trials adds new examples from across the agency’s drug review divisions.
A Skeptical Take on Current Alzheimer’s Therapy: FDA’s Temple Says Problem Is Drugs, Not Endpoints
When it comes to Alzheimer’s Drug development, FDA’s Bob Temple firmly believes regulatory standards are not the problem. “You just need a drug that works.”
Temple: FDASIA Directs FDA To Learn To Use Existing Authority
CDER’s Robert Temple says FDASIA mostly restates existing FDA authority, but also tells the agency it must better communicate what authority it has and how it will use it.